Skip to content

Corvus Pharmaceuticals, Inc.

CRVS· NasdaqCore metricsCIK 1626971

Pharmaceutical preparations553 peers

Last sale
Nov 12, 2026 · -7.58%
Market cap
$895.41M
84.35M shares
Filings
585
—
—
—
-$20.34M
Q3 2026N/M FY25 yoy
-$21.36M
Q3 2026N/M FY25 yoy
-$38.73M
Q3 2026derivedN/M FY25 yoy
-$0.22
Q3 2026N/M FY25 yoy
$15.01M
Q3 2026−47.6% FY25 yoy
$895.41M
—
—
4.3×
-3.68%
—

FY2025 figures · derived

Price

$10.62+29.93%+$2.45past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Research And Development

$33.72MFY 2025
$46.31M0FY 2014FY 2019FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$33,719,000reported
FY 20242024-12-31$19,385,000reported
FY 20232023-12-31$16,526,000reported
FY 20212022-12-31$24,468,000reported
FY 20202021-12-31$29,115,000reported
FY 20192020-12-31$31,830,000reported
FY 20182018-12-31$38,586,000reported
FY 20172017-12-31$46,305,000reported
FY 20162016-12-31$29,356,000reported
FY 20152015-12-31$11,352,000reported
FY 20142014-12-31$38,000reported

Pharmaceutical preparations

Corvus Pharmaceuticals, Inc. is the 149th largest of the 554 covered companies the SEC files under this code, by market cap. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Corvus Pharmaceuticals, Inc. · CIK 1626971 · Engraved from SEC EDGAR